491 related articles for article (PubMed ID: 27598335)
1. Urinary Polyamines: A Pilot Study on Their Roles as Prostate Cancer Detection Biomarkers.
Tsoi TH; Chan CF; Chan WL; Chiu KF; Wong WT; Ng CF; Wong KL
PLoS One; 2016; 11(9):e0162217. PubMed ID: 27598335
[TBL] [Abstract][Full Text] [Related]
2. Urinary microRNA-based signature improves accuracy of detection of clinically relevant prostate cancer within the prostate-specific antigen grey zone.
Salido-Guadarrama AI; Morales-Montor JG; Rangel-Escareño C; Langley E; Peralta-Zaragoza O; Cruz Colin JL; Rodriguez-Dorantes M
Mol Med Rep; 2016 Jun; 13(6):4549-60. PubMed ID: 27081843
[TBL] [Abstract][Full Text] [Related]
3. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.
Tomlins SA; Day JR; Lonigro RJ; Hovelson DH; Siddiqui J; Kunju LP; Dunn RL; Meyer S; Hodge P; Groskopf J; Wei JT; Chinnaiyan AM
Eur Urol; 2016 Jul; 70(1):45-53. PubMed ID: 25985884
[TBL] [Abstract][Full Text] [Related]
4. Expression of PCA3 and PSA genes as a biomarker for differential diagnosis of nodular hyperplasia and prostate cancer.
Coelho FF; Guimarães FL; Cabral WL; Salles PG; Mateo EC; Nogueira e Nogueira LM; Fonseca CE; Gomes KB
Genet Mol Res; 2015 Oct; 14(4):13519-31. PubMed ID: 26535666
[TBL] [Abstract][Full Text] [Related]
5. Wisteria floribunda Agglutinin and Its Reactive-Glycan-Carrying Prostate-Specific Antigen as a Novel Diagnostic and Prognostic Marker of Prostate Cancer.
Hagiwara K; Tobisawa Y; Kaya T; Kaneko T; Hatakeyama S; Mori K; Hashimoto Y; Koie T; Suda Y; Ohyama C; Yoneyama T
Int J Mol Sci; 2017 Jan; 18(2):. PubMed ID: 28134773
[No Abstract] [Full Text] [Related]
6. A novel urinary mRNA signature using the droplet digital polymerase chain reaction platform improves discrimination between prostate cancer and benign prostatic hyperplasia within the prostate-specific antigen gray zone.
Kang HW; Lee HY; Byun YJ; Jeong P; Yoon JS; Kim DH; Kim WT; Kim YJ; Lee SC; Yun SJ; Kim WJ
Investig Clin Urol; 2020 Jul; 61(4):411-418. PubMed ID: 32665998
[TBL] [Abstract][Full Text] [Related]
7. Integration of lipidomics and transcriptomics unravels aberrant lipid metabolism and defines cholesteryl oleate as potential biomarker of prostate cancer.
Li J; Ren S; Piao HL; Wang F; Yin P; Xu C; Lu X; Ye G; Shao Y; Yan M; Zhao X; Sun Y; Xu G
Sci Rep; 2016 Feb; 6():20984. PubMed ID: 26865432
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic and prognostic value of serum miR-15a and miR-16-1 expression among egyptian patients with prostate cancer.
Zidan HE; Abdul-Maksoud RS; Elsayed WSH; Desoky EAM
IUBMB Life; 2018 May; 70(5):437-444. PubMed ID: 29522280
[TBL] [Abstract][Full Text] [Related]
9. Investigation on core-fucosylated prostate-specific antigen as a refined biomarker for differentiation of benign prostate hyperplasia and prostate cancer of different aggressiveness.
Lang R; Rolny V; Leinenbach A; Karl J; Swiatek-de Lange M; Kobold U; Schrader M; Krause H; Mueller M; Vogeser M
Tumour Biol; 2019 Mar; 41(3):1010428319827223. PubMed ID: 30907281
[TBL] [Abstract][Full Text] [Related]
10. Clinical utility of a serum biomarker panel in distinguishing prostate cancer from benign prostate hyperplasia.
Kiebish MA; Tekumalla P; Ravipaty S; Dobi A; Srivastava S; Wu W; Patil S; Friss T; Klotz A; Srinivasan A; Cullen J; Rosner IL; Ali A; Laszlo S; Petrovic M; Fleshner N; Garren J; Miller G; Mahaveer Chand N; Rodrigues LO; Granger E; Kellogg MD; Luan S; Diamandis E; Akmaev VR; Sarangarajan R; Bountra C; Freedland SJ; McLeod DG; Narain NR
Sci Rep; 2021 Jul; 11(1):15052. PubMed ID: 34302010
[TBL] [Abstract][Full Text] [Related]
11. Plasma Sarcosine Measured by Gas Chromatography-Mass Spectrometry Distinguishes Prostatic Intraepithelial Neoplasia and Prostate Cancer from Benign Prostate Hyperplasia.
Markin PA; Brito A; Moskaleva N; Fodor M; Lartsova EV; Shpot YV; Lerner YV; Mikhajlov VY; Potoldykova NV; Enikeev DV; Lyundup AV; Appolonova SA
Lab Med; 2020 Nov; 51(6):566-573. PubMed ID: 32161964
[TBL] [Abstract][Full Text] [Related]
12. Molecular Diagnostic of Prostate Cancer From Body Fluids Using Methylation-Specific PCR (MS-PCR) Method.
Minciu R; Dumache R; Gheorghe P; Daminescu L; Rogobete AF; Ionescu D
Clin Lab; 2016; 62(6):1183-6. PubMed ID: 27468582
[TBL] [Abstract][Full Text] [Related]
13. MiR-145 detection in urinary extracellular vesicles increase diagnostic efficiency of prostate cancer based on hydrostatic filtration dialysis method.
Xu Y; Qin S; An T; Tang Y; Huang Y; Zheng L
Prostate; 2017 Jul; 77(10):1167-1175. PubMed ID: 28617988
[TBL] [Abstract][Full Text] [Related]
14. POLYAMINES AS NEW POTENTIAL BIOMARKERS FOR DIFFERENTIAL DIAGNOSIS OF PROSTATE CANCER AND ESTIMATION OF ITS AGGRESSIVENESS.
Zaletok SP; Klenov OO; Bentrad VV; Prylutskyi MP; Vitruk YV; Stakhovsky EO; Timoshenko AV
Exp Oncol; 2022 Aug; 44(2):148-154. PubMed ID: 35964654
[TBL] [Abstract][Full Text] [Related]
15. Using Genetic and Epigenetic Markers to Improve Differential Diagnosis of Prostate Cancer and Benign Prostatic Hyperplasia by Noninvasive Methods in Mexican Patients.
Sánchez BE; Aguayo A; Martínez B; Rodríguez F; Marmolejo M; Svyryd Y; Luna L; Muñoz LA; Jiménez MA; Sotomayor M; Vargas V F; Mutchinick OM
Clin Genitourin Cancer; 2018 Aug; 16(4):e867-e877. PubMed ID: 29571584
[TBL] [Abstract][Full Text] [Related]
16. Screening, identification of prostate cancer urinary biomarkers and verification of important spots.
Zhao H; Zhao X; Lei T; Zhang M
Invest New Drugs; 2019 Oct; 37(5):935-947. PubMed ID: 30610587
[TBL] [Abstract][Full Text] [Related]
17. Likelihood of prostate cancer based on prostate-specific antigen density by MRI: retrospective analysis.
Mueller-Lisse UG; Mueller-Lisse UL; Haller S; Schneede P; Scheidler JE; Schmeller N; Hofstetter AG; Reiser MF
J Comput Assist Tomogr; 2002; 26(3):432-7. PubMed ID: 12016375
[TBL] [Abstract][Full Text] [Related]
18. Detection of miRNAs in urine of prostate cancer patients.
Stuopelytė K; Daniūnaitė K; Jankevičius F; Jarmalaitė S
Medicina (Kaunas); 2016; 52(2):116-24. PubMed ID: 27170485
[TBL] [Abstract][Full Text] [Related]
19. The utility of urine-circulating miRNAs for detection of prostate cancer.
Stuopelyte K; Daniunaite K; Bakavicius A; Lazutka JR; Jankevicius F; Jarmalaite S
Br J Cancer; 2016 Sep; 115(6):707-15. PubMed ID: 27490805
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic and prognostic scoring system for prostate cancer using urine and plasma biomarkers.
Ma W; Diep K; Fritsche HA; Shore N; Albitar M
Genet Test Mol Biomarkers; 2014 Mar; 18(3):156-63. PubMed ID: 24512523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]